Tóth Dezső, Bíró Adrienn, Varga Zsolt, Török Miklós, Árkosy Péter
Department of General Surgery, Kenézy Gyula Teaching Hospital, Debrecen 4031, Hungary.
Chin J Cancer Res. 2017 Aug;29(4):323-332. doi: 10.21147/j.issn.1000-9604.2017.04.05.
The Union for International Cancer Control (UICC) Node (N) classification is the most common used staging method for the prognosis of gastric cancer. It demands adequate, at least 16 lymph nodes (LNs) to be dissected; therefore different staging systems were invented.
Between March 2005 and March 2010, 164 patients were evaluated at the Department of General Surgery in the Kenézy Gyula Hospital and at the Department of General, Thoracic and Vascular Surgery in the Kaposi Mór Hospital. The 6th, 7th and 8th UICC N-staging systems, the number of examined LNs, the number of harvested negative LNs, the metastatic lymph node ratio (MLR) and the log odds of positive LNs (LODDS) were determined to measure their 5-year survival rates and to compare them to each other.
The overall 5-year survival rate for all patients was 55.5% with a median overall survival time of 102 months. The tumor stage, gender, UICC N-stages, MLR and the LODDS were significant prognostic factors for the 5-year survival with univariate analysis. The 6th UICC N-stage did not follow the adequate risk in comparing N2 . N0 and N3 . N0 with multivariate investigation. Comparison of performances of the residual N classifications proved that the LODDS system was first in the prediction of prognosis during the evaluation of all patients and in cases with less than 16 harvested LNs. The MLR gave the best prognostic prediction when adequate (more than or equal to 16) lymphadenectomy was performed.
We suggest the application of LODDS system routinely in western patients and the usage of MLR classification in cases with extended lymphadenectomy.
国际癌症控制联盟(UICC)的淋巴结(N)分类是胃癌预后最常用的分期方法。它要求至少切除16枚淋巴结;因此发明了不同的分期系统。
2005年3月至2010年3月期间,对凯内齐·久洛医院普通外科以及卡波西·莫尔医院普通、胸科和血管外科的164例患者进行了评估。确定了第6版、第7版和第8版UICC N分期系统、检查的淋巴结数量、切除的阴性淋巴结数量、转移淋巴结比率(MLR)和阳性淋巴结对数优势比(LODDS),以测量其5年生存率并相互比较。
所有患者的总体5年生存率为55.5%,中位总生存时间为102个月。单因素分析显示,肿瘤分期、性别、UICC N分期、MLR和LODDS是5年生存的重要预后因素。多因素研究比较N2.N0和N3.N0时,第6版UICC N分期未遵循适当风险。残余N分类性能比较证明,在评估所有患者以及切除的淋巴结少于16枚的病例中,LODDS系统在预后预测方面排名第一。当进行充分(大于或等于16枚)淋巴结清扫时,MLR给出了最佳预后预测。
我们建议在西方患者中常规应用LODDS系统,在进行扩大淋巴结清扫的病例中使用MLR分类。